| Project Detail |
INTRODUCTION: MediWound develops wound care solutions, for chronic wounds and severe burns. The Company’s leading drug candidate under development and the subject of this EIC Accelerator project is EscharEx®, a groundbreaking bioactive therapy specifically targeting the debridement of Diabetic Foot Ulcers (DFUs) and other challenging chronic wounds. EscharEx is poised to revolutionize the standard of care (SOC) that for many patients is ineffective. EscharEx - A GAME-CHANGER IN CHRONIC WOUND CARE: EscharEx is a complex mixture of proteolytic enzymes, primarily bromelain, designed to selectively remove necrotic tissue and biofilm from chronic wounds. This process is highly efficient and does not harm viable tissue, providing an optimal wound bed for healing. Unlike traditional knife-based debridement, which can be traumatic and painful, EscharEx offers a non-surgical alternative that is swift, safe and effective. This aspect is especially critical for diabetic patients, often elderly and suffering from co-morbidities, who may find surgical options less suitable. The currently available non-surgical options are notoriously slow and ineffective, causing delays to the wound healing process, and resulting in significant incremental costs and poorer overall outcomes. CLINICAL PROGRESS AND VALIDATION: MediWounds confidence in EscharEx stems from the outcomes of three Phase 2 clinical studies. These studies demonstrated the therapys rapid, safe, and effective debridement of DFUs and Venous Leg Ulcers (VLUs). Additionally, EscharEx shares the same active pharmaceutical ingredient as NexoBrid, MediWounds EMA and FDA-approved drug product for debridement of severe burn wounds. The consistency of active ingredients and similarity of indications between these two drugs provides additional support for the increased probability of success for EscharEx development and highlight the scientific rigor behind EscharExs development. |
